Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaci.2018.01.008PMID 29382593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Weight‐adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed‐Dose Subcutaneous Mepolizumab

  2018cited by this paper
• Hematopoietic Processes in Eosinophilic Asthma

  2017cited by this paper
• Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

  2017cited by this paper
• Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone‐dependent severe asthma

  2016cited by this paper
• Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.

  2016cited by this paper
• Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

  2016cited by this paper
• Sample sizes for clinical trials using sputum eosinophils as a primary outcome

  2013cited by this paper
• MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.

  2010cited by this paper
• A look at the pathogenesis of asthma: the need for a change in direction.

  2010cited by this paper
• Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements.

  1996cited by this paper

• The Role of Biologics in Reducing Mucous Plug Burden in Asthma.

  2025cites this paper
• Benralizumab: Bringing winds of change to eosinophil-associated diseases

  2025cites this paper
• Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti-IL-5/5Rα biologics.

  2025cites this paper
• Biologic Management in Severe Asthma for Adults: An American College of Chest Physician Clinical Practice Guideline.

  2025cites this paper
• Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study

  2025cites this paper
• Real-world effectiveness of biologic therapy in allergic bronchopulmonary aspergillosis.

  2025cites this paper
• Mepolizumab to benralizumab: A case series of a biologic switch in severe asthma

  2025cites this paper
• A population of c-kit+ IL-17A+ ILC2s in sputum from individuals with severe asthma supports ILC2 to ILC3 trans-differentiation.

  2025cites this paper
• The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis.

  2025cites this paper
• Achieving remission in severe asthma

  2025cites this paper
• TNF Superfamily and ILC2 Activation in Asthma

  2024cites this paper
• Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

  2024cites this paper
• Skin Surface Lipid-RNA Profile Obtained from Patients with Severe Asthma After Benralizumab Treatment

  2024cites this paper
• Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils

  2024cites this paper
• Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial

  2024cites this paper
• Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation

  2024cites this paper
• Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma

  2024cites this paper
• Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

  2024cites this paper
• Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation

  2024cites this paper
• Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

  2023cites this paper
• Treatment of allergic asthma – new perspectives and therapeutic approaches

  2023cites this paper
• Human bocavirus 1 coinfection is associated with decreased cytokine expression in the rhinovirus‐induced first wheezing episode in children

  2023cites this paper
• Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial.

  2023cites this paper
• Eosinophils—from cradle to grave

  2023cites this paper
• Benralizumab for eosinophilic granulomatosis with polyangiitis

  2023cites this paper
• Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma

  2023cites this paper
• Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

  2023cites this paper
• Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation

  2022cites this paper
• Experience with the use of immunobiological drugs in the treatment of patients with severe bronchial asthma and comorbidities

  2022cites this paper
• Effects of Benralizumab on Three-Dimensional Computed Tomography Analysis in Severe Eosinophilic Asthma

  2022cites this paper
• Cytokine expression in rhinovirus- vs. respiratory syncytial virus-induced first wheezing episode and its relation to clinical course

  2022cites this paper
• Recent advances in the treatment of childhood asthma: a clinical pharmacology perspective

  2022cites this paper
• The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma

  2022cites this paper
• An introduction to eosinophils and their biology

  2022cites this paper
• Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences

  2022cites this paper
• The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions

  2022cites this paper
• Biologics in severe asthma – a molecular perspective

  2022cites this paper
• Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

  2022cites this paper
• Biologics in Asthma: A Molecular Perspective to Precision Medicine

  2022cites this paper
• The immunology of switching biologics in severe eosinophilic asthma patients.

  2021cites this paper
• Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma

  2021cites this paper
• Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

  2021cites this paper
• Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

  2021cites this paper
• Eosinophil Lineage-Committed Progenitors as a Therapeutic Target for Asthma

  2021cites this paper
• Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab

  2021cites this paper
• Treating severe asthma: Targeting the IL‐5 pathway

  2021cites this paper
• Clinical effects and immune modulation of biologics in asthma.

  2021cites this paper
• Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

  2021cites this paper
• Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era

  2021cites this paper
• Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

  2021cites this paper
• The impact of asthma-exclusive nursing scheme on the treatment effect of asthma patients.

  2021cites this paper
• Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital

  2021cites this paper
• The Role of Innate Lymphoid Cells in Chronic Respiratory Diseases

  2021cites this paper
• Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

  2021cites this paper
• Peptide Targeting of PDZ-Dependent Interactions as Pharmacological Intervention in Immune-Related Diseases

  2021cites this paper
• Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.

  2021cites this paper
• Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

  2021cites this paper
• Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity

  2021cites this paper
• How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?

  2020cites this paper
• Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma

  2020cites this paper
• Практические рекомендации по выбору иммунобиологического препарата для лечения тяжелой бронхиальной астмы Т2-эндотипа

  2020cites this paper
• Asthma exacerbations on benralizumab are largely non‐eosinophilic

  2020cites this paper
• Predictors of response to anti‐IL‐5 biologics

  2020cites this paper
• Th2 cell markers in peripheral blood increase during an acute asthma exacerbation

  2020cites this paper
• Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.

  2020cites this paper
• Exacerbations of severe asthma while on Anti-IL5 biologicals.

  2020influential citation
• Effects of anti-T2 biologic treatment on lung ventilation evaluated by MRI in adults with prednisone-dependent asthma.

  2020cites this paper
• Sesamol Alleviates Airway Hyperresponsiveness and Oxidative Stress in Asthmatic Mice

  2020cites this paper
• Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma

  2020cites this paper
• Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma

  2020cites this paper
• Persistence of sinonasal disease despite mepolizumab.

  2020cites this paper
• Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.

  2020cites this paper
• Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab

  2020influential citation
• Exacerbations of severe asthma while on Anti-IL5 biologicals

  2020influential citation
• Secondary loss of response to mepolizumab in severe eosinophilic asthma.

  2020cites this paper
• Plaučių vėžio imunologiniai mechanizmai

  2020cites this paper
• Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.

  2019cites this paper
• The emergence of new biologics for severe asthma.

  2019cites this paper
• Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.

  2019cites this paper
• Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma.

  2019cites this paper
• The role of type 2 innate lymphoid cells in eosinophilic asthma

  2019cites this paper
• Practical Considerations in the Management of Eosinophilic Asthma

  2019cites this paper
• Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.

  2019cites this paper
• Obesity and adult asthma: diagnostic and management challenges

  2019cites this paper
• Advances in Asthma, ACO, and Related Biologics in 2018.

  2019cites this paper
• Critical Points on the Use of Biologicals in Allergic Diseases and Asthma

  2019cites this paper
• Targeting eosinophils: severe asthma and beyond

  2019cites this paper
• Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.

  2019cites this paper
• Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

  2018cites this paper
• Immunological and hematological effects of IL‐5(Rα)‐targeted therapy: An overview

  2018cites this paper
• Endotypes in allergic diseases

  2018cites this paper
• Autoimmune Responses in Severe Asthma

  2018cites this paper
• Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma

  2018cites this paper
• Group 2 Innate Lymphoid Cells are Increased in Patients with Moderate-To-Severe Atopic Dermatitis

  2018cites this paper
• The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies

  2018cites this paper
• Chronic rhinosinusitis: pathogenesis, therapy options, and more

  2018cites this paper
• Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma.

  2018cites this paper
• Advances in asthma in 2017: Mechanisms, biologics, and genetics

  2018cites this paper
• BIOLOGICAL THERAPY WITH BENRALIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: ADVANTAGES AND UNANSWERED QUESTIONS

  year unknowncites this paper